

Curriculum Vitae

Marcus A. Mall Professor, Dr. med.
d.o.b. October 05th, 1968, in Stuttgart, Germany

University Education

2007 Habilitation, Pediatrics and Adolescent Medicine, University of Heidelberg
1997 Doctorate, Medicine (M.D.), University of Freiburg
1990–1997 Studies of Medicine University of Freiburg, Germany and University College London School of Medicine, London, UK

Scientific Career

Since 2025 Principal Investigator, Cluster of Excellence ImmunoPreCept
Since 2021 Deputy Speaker, CRC 1449 “Dynamic Hydrogels at Biointerfaces” (DFG)
Since 2021 Speaker and Director, Berlin site of the German Center for Child and Adolescent Health (DZKJ)
Since 2018 Full Professor (W3) of Pediatric Respiratory Medicine and Immunology and Director of the Department of Pediatric Respiratory Medicine, Immunology and Critical Care Medicine, Charité - Universitätsmedizin Berlin
Since 2018 BIH Professor, Berlin Institute of Health (BIH)
2012–2018 Director of the Department of Translational Pulmonology and Chairman of the Translational Lung Research Center Heidelberg (TLRC)
Since 2012 Coordinator, Disease Area Cystic Fibrosis, German Center for Lung Research (DZL)
2011–2018 Founding Director and Member of the Executive Board, German Centre for Lung Research (DZL)
2009–2012 Heisenberg Professorship (W3) for Translational Pulmonology (DFG) and Head of the Division of Pediatric Pulmonology & Allergy and Cystic Fibrosis Center, Department of Pediatrics, University of Heidelberg
2006–2018 Group leader at the Molecular Medicine Partnership Unit (MMPU) of the University of Heidelberg and the European Molecular Biology Laboratory (EMBL)
2006–2018 Faculty Member of the Hartmut Hoffmann-Berling International Graduate School of Molecular & Cellular Biology Heidelberg (HBIGS)
2005–2009 Group leader of EU-funded Independent Junior Research Group “Cystic Fibrosis / Chronic Airway Disease” (Marie Curie Excellence Team)
2004–2006 Fellow in Pediatric Pulmonology, Department of Pediatrics, University of Heidelberg
2003–2004 Assistant Professor, School of Medicine, UNC, Chapel Hill, NC, USA
2000–2003 Postdoc, CF/Pulmonary Research and Treatment Center, School of Medicine, University of North Carolina at Chapel Hill (UNC), Chapel Hill, NC, USA
1997–2000 Resident, University Children’s Hospital, University of Freiburg

Awards and Honors

2024 Elected Member of the German National Academy of Sciences Leopoldina
2022 Science Breakthrough of the Year 2022 Award in Life Sciences, Falling Walls Foundation
2020 Adalbert Czerny Prize, German Society of Pediatrics and Adolescent Medicine (DGKJ)
2020 Excellence Award for Research in Cystic Fibrosis, European Respiratory Society (ERS)
2018 Einstein-Professorship, Einstein Foundation Berlin
Since 2017 Fellow of ERS (FERS)
2009 Heisenberg-Professorship, German Research Foundation (DFG)
2009 Research Award, German Society of Pulmonology (DGP)
2005 Marie Curie Excellence Grant (EU 6. Framework Programme)
2005 Johannes Wenner Prize, German Society of Pediatric Pulmonology (GPP)
2000–2002 Research Fellowship, German Research Foundation (DFG)
1997 Adolf Windorfer Prize, German Cystic Fibrosis Association

Citation Record

Total citations: 21,582; h-index:77 (Web of Science March 06th, 2026)

Top-10 selected Publications

Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, **Mall MA***, Fajac I*. Elexacaftor/Tezacaftor/Ivacaftor for Cystic Fibrosis and Rare CFTR Variants: In Vitro Translation to a Phase 3, Double-Blind, Randomized, Placebo-controlled Trial and Real-World Study. *Am J Respir Crit Care Med* 2026. Epub ahead of print. (*equal contribution)

Nussstein H, Urbantat RM, Fentker K, Loewe A, Duerr J, Haji M, Doellinger F, Stahl M, Graeber SY, Gradzielski M, Röhmel J, Mertins P, Schaupp L, **Mall MA**. Changes in Sputum Viscoelastic Properties and Airway Inflammation in Primary Ciliary Dyskinesia are Comparable to Cystic Fibrosis on Elexacaftor/Tezacaftor/Ivacaftor Therapy. *Eur Respir J* 2026;67:2500616.

Loske J, Voller M, Lukassen S, Stahl M, Thurmann L, Seegebarth A, Rohmel J, Wisniewski S, Messingschlager M, Lorenz S, Klages S, Eils R, Lehmann I, **Mall MA***, Graeber SY*, Trump S*. Pharmacological Improvement of CFTR Function Rescues Airway Epithelial Homeostasis and Host Defense in Children with Cystic Fibrosis. *Am J Respir Crit Care Med* 2024;209:1338-1350. (*equal contribution)

Schaupp L, Addante A, Voller M, Fentker K, Kuppe A, Bardua M, Duerr J, Piehler L, Rohmel J, Thee S, Kirchner M, Ziehm M, Lauster D, Haag R, Gradzielski M, Stahl M, Mertins P, Boutin S, Graeber SY, **Mall MA**. Longitudinal Effects of Elexacaftor/Tezacaftor/Ivacaftor on Sputum Viscoelastic Properties, Airway Infection and Inflammation in Patients with Cystic Fibrosis. *Eur Respir J* 2023;62:2202153.

Mall MA, Brugha R, Gartner S, Legg J, Moeller A, Mondejar-Lopez P, Prais D, Pressler T, Ratjen F, Reix P, Robinson PD, Selvadurai H, Stehling F, Ahluwalia N, Arteaga-Solis E, Bruinsma BG, Jennings M, Moskowitz SM, Noel S, Tian S, Weinstock TG, Wu P, Wainwright CE, Davies JC. Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor in Children 6 Through 11 Years of Age with Cystic Fibrosis Heterozygous for F508del and a Minimal Function Mutation: A Phase 3B, Randomized, Placebo-Controlled Study. *Am J Respir Crit Care Med* 2022;206:1361-1369.

Graeber SY, Vitzthum C, Pallenberg ST, Naehrlich L, Stahl M, Rohrbach A, Drescher M, Minso R, Ringshausen FC, Rueckes-Nilges C, Klajda J, Berges J, Yu Y, Scheuermann H, Hirtz S, Sommerburg O, Dittrich AM, Tummeler B, **Mall MA**. Effects of Elexacaftor/Tezacaftor/Ivacaftor Therapy on CFTR Function in Patients with Cystic Fibrosis and One or Two F508del Alleles. *Am J Respir Crit Care Med* 2022;205:540-549.

Loske J, Rohmel J, Lukassen S, Stricker S, Magalhaes VG, Liebig J, Chua RL, Thurmann L, Messingschlager M, Seegebarth A, Timmermann B, Klages S, Ralser M, Sawitzki B, Sander LE, Corman VM, Conrad C, Laudi S, Binder M*, Trump S*, Eils R*, **Mall MA***, Lehmann I*. Pre-activated antiviral innate immunity in the upper airways controls early SARS-CoV-2 infection in children. *Nat Biotechnol* 2022;40:319-324. (*equal contribution)

Barry PJ*, **Mall MA***, Alvarez A, Colombo C, de Winter-de Groot KM, Fajac I, McBennett KA, McKone EF, Ramsey BW, Sutharsan S, Taylor-Cousar JL, Tullis E, Ahluwalia N, Jun LS, Moskowitz SM, Prieto-Centurion V, Tian S, Waltz D, Xuan F, Zhang Y, Rowe SM, Polineni D. Triple Therapy for Cystic Fibrosis Phe508del-Gating and -Residual Function Genotypes. *N Engl J Med* 2021;385:815-825. (*equal contribution)

Middleton PG*, **Mall MA***, Drevinek P, Lands LC, McKone EF, Polineni D, Ramsey BW, Taylor-Cousar JL, Tullis E, Vermeulen F, Marigowda G, McKee CM, Moskowitz SM, Nair N, Savage J, Simard C, Tian S, Waltz D, Xuan F, Rowe SM, Jain R. Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. *N Engl J Med* 2019;381:1809-1819. (*equal contribution)

Mall M, Grubb BR, Harkema JR, O'Neal WK, Boucher RC. Increased airway epithelial Na⁺ absorption produces cystic fibrosis-like lung disease in mice. *Nat Med* 2004;10:487-493.